Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone AcetateWataru Fukuokaya, Takahiro Kimura, Keiichiro Mori et al.|JAMA Network Open|2024Cited by 15
Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinomaWataru Fukuokaya, Shin Egawa, Takahiro Kimura et al.|Cancer Immunology Immunotherapy|2021Cited by 11
The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiationSoshi Kadena, Takahiro Kimura, Fumihiko Urabe et al.|International Journal of Clinical Oncology|2023Cited by 7
Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapyYu Imai, Takahiro Kimura, Fumihiko Urabe et al.|International Journal of Clinical Oncology|2023Cited by 7
Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumabWataru Fukuokaya, Shin Egawa, Takahiro Kimura et al.|British Journal of Urology|2020Cited by 6